Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes.

Published

Journal Article

OBJECTIVE: To investigate the use of prasugrel after percutaneous coronary intervention (PCI) in African American (AA) patients presenting with acute coronary syndrome (ACS). BACKGROUND: AA patients are at higher risk for adverse cardiovascular outcomes after PCI and may derive greater benefit from the use of potent antiplatelet therapy. METHODS: Using the multicenter PROMETHEUS observational registry of ACS patients treated with PCI, we grouped patients by self-reported AA or other races. Clinical outcomes at 90-day and 1-year included non-fatal myocardial infarction (MI), major adverse cardiac events (composite of death, MI, stroke, or unplanned revascularization) and major bleeding. RESULTS: The study population included 2,125 (11%) AA and 17,707 (89%) non-AA patients. AA patients were younger, more often female (46% vs. 30%) with a higher prevalence of diabetes mellitus, chronic kidney disease, and prior coronary intervention than non-AA patients. Although AA patients more often presented with troponin (+) ACS, prasugrel use was much less common in AA vs. non-AA (11.9% vs. 21.4%, respectively, P = 0.001). In addition, the use of prasugrel increased with the severity of presentation in non-AA but not in AA patients. Multivariable logistic regression showed AA race was an independent predictor of reduced use of prasugrel (0.42 [0.37-0.49], P < 0.0001). AA race was independently associated with a significantly higher risk of MI at 90-days and 1 year after PCI. CONCLUSIONS: Despite higher risk clinical presentation and worse 1-year ischemic outcomes, AA race was an independent predictor of lower prasugrel prescription in a contemporary population of ACS patients undergoing PCI.

Full Text

Duke Authors

Cited Authors

  • Faggioni, M; Baber, U; Chandrasekhar, J; Sartori, S; Weintraub, W; Rao, SV; Vogel, B; Claessen, B; Kini, A; Effron, M; Ge, Z; Keller, S; Strauss, C; Snyder, C; Toma, C; Weiss, S; Aquino, M; Baker, B; Defranco, A; Bansilal, S; Muhlestein, B; Kapadia, S; Pocock, S; Poddar, KL; Henry, TD; Mehran, R

Published Date

  • July 1, 2019

Published In

Volume / Issue

  • 94 / 1

Start / End Page

  • 53 - 60

PubMed ID

  • 30656812

Pubmed Central ID

  • 30656812

Electronic International Standard Serial Number (EISSN)

  • 1522-726X

Digital Object Identifier (DOI)

  • 10.1002/ccd.28033

Language

  • eng

Conference Location

  • United States